Global Head of HTA Strategy
Sanofi
Nathalie Largeron is Head of Global Health Technology Assessment (HTA) Strategy within Sanofi. In this role, she leads Sanofi efforts on HTA strategy and internal alignment. She also represents the company on HTA related topics with external stakeholders, including HTA bodies and policy organizations, industry associations and public health institutions.
Nathalie has a strong understanding of the role of market access, health economics, and HTA in clinical drug development process, pipeline strategy and life-cycle management. She joined Sanofi in 2017 where she created the Global Health Economics and Value assessment department within Sanofi’s Vaccines Business unit and led the team during nearly 5 years.
Before joining Sanofi, she has been working 14 years in several European roles, in the field of market access and outcomes research at Sanofi Pasteur MSD, a joint venture between Sanofi and Merck & Co, dedicated to the commercialization of vaccines in Europe.
Today Nathalie is an active member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) HTA Working Group where she is engaged in the debate and process related to the implementation of the new HTA regulation in Europe, she contributes also to the Vaccines Europe Access Working Group. She published more than 35 peer-reviewed papers and is a reviewer of several scientific journals. She is a member of ISPOR & HTAi.
Nathalie is a pharmacist, holds a Master’s in health economics from the University of Lyon, France and a post-graduate degree in epidemiology.
Disclosure information not submitted.
Key Trends Impacting HTA and Regulatory Interface
Tuesday, May 7, 2024
11:30 – 12:30 CEST